Treatment of schizophrenia and other psychiatric disorders, including supportive therapy in patients who have had a response to therapy, in order to prevent relapse; short term treatment of severe aggression or severe mental symptoms in patients with dementia if there is a threat of harm to themselves or others; treatment of manic episodes in bipolar disorders (auxiliary therapy in combination with normotimics as initial treatment or monotherapy for a period of up to 12 weeks); symptomatic treatment of defiant oppositional disorders or other social behavior disorders in children, adolescents, and adults with lower-than-average mental development or mental retardation who have manifestations of destructive behavior (impulsivity, autoagression); symptomatic treatment of autistic disorders in children aged 5 years and older, whose symptoms range from hyperactivity to irritability (including aggression, self-harm, anxiety, and pathological cyclical actions).
Composition and form of release
Rispolept is available in tablets and oral solution. The main active ingredient of the drug is risperidone.
Rispolept is used to treat patients suffering from various forms of schizophrenia, as well as patients with the first episode of psychosis and other psychotic disorders, accompanied by the development of severe negative or productive symptoms, such as hostility, suspicion, poor speech, social and emotional withdrawal, impaired thinking, hallucinations.
The drug can be used in the treatment of patients with schizoaffective disorders and a form of schizophrenia, accompanied by the development of affective symptoms: anxiety, fear, depression.
Rispolept is used to prevent the onset of acute psychotic conditions in patients suffering from chronic schizophrenia. In addition, the drug can be used for the prophylaxis and therapy of behavioral disorders in patients with dementia, accompanied by the development of increased aggression, behavior disorders and psychotic symptoms in the patient. Also Rispolept can be used in the complex treatment of bipolar disorders, in which manic episodes are observed.
Rispolept is not used during lactation, for the treatment of children under 15 years of age and hypersensitivity to risperidone.
The drug is prescribed with caution to those who suffer from cardiovascular diseases, impaired cardiac muscle conduction, cerebrovascular accident, Parkinson’s disease and suffered myocardial infarction. Also, it is recommended to refrain from the appointment of Rispolepta if the patient has a history of convulsive syndrome, renal or hepatic failure, drug dependence, intestinal obstruction, brain neoplasms and pregnancy.
Application for pregnancy and lactation
Rispolept is not used to treat pregnant women. If treatment with the drug is necessary for a patient at the lactation stage, it is recommended to refuse breastfeeding.
Method of administration and dosage
When used in Rispolepta therapy, the dose is selected individually. The starting daily dose on the first day in the treatment of adults can be from 0.25 to 2 mg, on the 2nd day – 4 mg. In the future, the dose of the drug either remains unchanged or is adjusted depending on the patient’s condition and can range from 0.5 to 6 mg per day. Sometimes it is advisable to increase the dose more slowly, as well as to prescribe a lower maintenance and initial dose. The maximum daily dose of Rispolepta is 16 mg.
When taking Rispolepta in high doses, the patient may experience drowsiness, tachycardia, hypotension and the development of extrapyramidal symptoms. The patient is prescribed gastric lavage, the intake of enerosorbents and symptomatic treatment.
When treating with Rispolept, a patient may develop undesirable symptoms from the central nervous system, gastrointestinal tract and cardiovascular system. Also, in some patients with prolonged use of the drug, allergic reactions occur.
Storage conditions and periods
It is recommended to store Rispolept in a dark place at a temperature of 15 to 30 degrees. The shelf life is 3 years.